- Home
- ANNX
ANNX
Annexon Inc.
as 11-07-2024 4:00pm EST
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 622.3M | IPO Year: | 2020 |
| Target Price: | $15.80 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.04 - $8.40 | Next Earning Date: | 11-19-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Annexon Inc. (ANNX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Yednock Ted | ANNX | EVP & CHIEF INNOVATION OFFICER | Oct 15 '24 | Sell | $7.41 | 5,408 | $40,073.28 | 71,365 | |
| Carson William H. | ANNX | Director | Oct 1 '24 | Buy | $5.97 | 3,200 | $19,104.00 | 22,400 | |
| Yednock Ted | ANNX | EVP & CHIEF INNOVATION OFFICER | Sep 19 '24 | Sell | $7.10 | 4,500 | $31,950.00 | 71,365 | |
| Yednock Ted | ANNX | EVP & CHIEF INNOVATION OFFICER | Sep 12 '24 | Sell | $6.16 | 5,500 | $33,880.00 | 71,365 | |
| Yednock Ted | ANNX | EVP & CHIEF INNOVATION OFFICER | Sep 5 '24 | Sell | $5.64 | 5,500 | $31,020.00 | 71,365 | |
| Yednock Ted | ANNX | EVP & CHIEF INNOVATION OFFICER | Aug 29 '24 | Sell | $5.95 | 5,500 | $32,725.00 | 71,365 |
Latest Annexon Inc. News
ANNX Breaking Stock News: Dive into ANNX Ticker-Specific Updates for Smart Investing
GlobeNewswire
17 days ago
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Simply Wall St.
18 days ago
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely
GlobeNewswire
23 days ago
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
24 days ago
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
GlobeNewswire
2 months ago
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress
GlobeNewswire
2 months ago
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio
GlobeNewswire
2 months ago
Annexon Biosciences to Participate in Upcoming September Investor Conferences
Compare ANNX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANNX Annexon Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.